INFORMING THE PATHWAY OF COPD TREATMENT (IMPACT STUDY) SINGLE INHALER TRIPLE THERAPY (FF/UMEC/VI) VERSUS UMEC/VI IN PATIENTS WITH COPD: COST-EFFECTIVENESS ANALYSIS FROM A SOCIETAL PERSPECTIVE IN QUEBEC

被引：1
|
作者：
Mursleen, S. [1 ]
Shah, D. [2 ]
Schroeder, M. [3 ]
Perdrizet, J. [2 ]
Ndirangu, K. [2 ]
Risebrough, N. [4 ]
Martin, A. [5 ]
机构：
[1] GSK, Mississauga, ON, Canada
[2] ICON Hlth Econ, New York, NY USA
[3] GSK, Brentford, England
[4] ICON, ICON Hlth Econ, Toronto, ON, Canada
[5] GSK, Uxbridge, Middx, England
来源：
VALUE IN HEALTH | 2018年 / 21卷
关键词：
D O I：
10.1016/j.jval.2018.09.2438
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PRS44
引用
收藏
页码：S411 / S411
页数：1
相关论文
共 50 条
  • [21] An Analysis of the IMPACT Trial Assessing Single-Inhaler Therapy with Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) Versus FF/VI and UMEC/VI Using a Composite Adverse Event Outcome in Patients with COPD
    Wells, J. M.
    Bhatt, S. P.
    Carr, T. F.
    Criner, G. J.
    Halpin, D. M. G.
    Han, M. K.
    Jain, R.
    Kaye, M. G.
    Kraft, M.
    Lipson, D. A.
    Mapel, D.
    Mammen, M. J.
    McEvoy, C.
    Midwinter, D.
    Singh, D.
    Wise, R.
    Dransfield, M. T.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2021, 203 (09)
  • [22] Single-inhaler fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) triple therapy versus tiotropium monotherapy in patients with COPD
    Sandeep Bansal
    Martin Anderson
    Antonio Anzueto
    Nicola Brown
    Chris Compton
    Thomas C. Corbridge
    David Erb
    Catherine Harvey
    Morrys C. Kaisermann
    Mitchell Kaye
    David A. Lipson
    Neil Martin
    Chang-Qing Zhu
    Alberto Papi
    npj Primary Care Respiratory Medicine, 31
  • [23] Single-inhaler fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) triple therapy versus tiotropium monotherapy in patients with COPD
    Bansal, Sandeep
    Anderson, Martin
    Anzueto, Antonio
    Brown, Nicola
    Compton, Chris
    Corbridge, Thomas C.
    Erb, David
    Harvey, Catherine
    Kaisermann, Morrys C.
    Kaye, Mitchell
    Lipson, David A.
    Martin, Neil
    Zhu, Chang-Qing
    Papi, Alberto
    NPJ PRIMARY CARE RESPIRATORY MEDICINE, 2021, 31 (01)
  • [24] TREATMENT EFFECTS OF FF/UMEC/VI VS FF/VI AND UMEC/VI IN COPD PATIENTS BY AIRFLOW LIMITATION SEVERITY: POST-HOC ANALYSES OF THE IMPACT STUDY
    Abbott, Carl
    Hilton, Emma
    Criner, Gerard
    Dransfield, Mark
    Halpin, David
    Han, Meilan
    Jones, Christine Elaine
    Kilbride, Sally
    Lange, Peter
    Martinez, Fernando
    Singh, Dave
    Wise, Robert
    Lipson, David
    CHEST, 2018, 154 (04) : 774A - 775A
  • [25] THE IMPACT TRIAL: IS SINGLE-INHALER TRIPLE THERAPY (FF/UMEC/VI) COST-EFFECTIVE VERSUS DUAL THERAPY WITH INHALED CORTICOSTEROID PLUS LONG-ACTING BETA AGONIST (FF/VI) IN PATIENTS WITH COPD IN SPAIN?
    Paly, V
    Vallejo-Aparicio, L. A.
    Schroeder, M.
    Martin, A.
    Izquierdo Alonso, J. L.
    Riesco Miranda, J. A.
    Soler Cataluna, J. J.
    Risebrough, N.
    Abreu, C.
    Biswas, C.
    Ismaila, A. S.
    VALUE IN HEALTH, 2019, 22 : S877 - S877
  • [26] COST-EFFECTIVENESS OF UMECLIDINIUM/VILANTEROL (UMEC/VI) VERSUS ACLIDINIUM/FORMOTEROL (ACL/ FOR) IN PATIENTS WITH COPD IN THE UNITED KINGDOM
    Shah, D.
    Martin, A.
    Kendall, R.
    Noorduyn, S. G.
    Dasari, P.
    Risebrough, N.
    Ismaila, A.
    VALUE IN HEALTH, 2023, 26 (12) : S190 - S191
  • [27] COST EFFECTIVENESS OF UMECLIDINIUM/VILANTEROL (UMEC/VI) COMBINATION THERAPY AMONG SYMPTOMATIC COPD PATIENTS
    Punekar, Y. S.
    Roberts, G.
    Ismaila, A.
    O'Leary, M.
    VALUE IN HEALTH, 2014, 17 (07) : A595 - A595
  • [28] COST-EFFECTIVENESS OF UMECLIDINIUM/VILANTEROL (UMEC/VI) VERSUS TIOTROPIUM/OLODATEROL (TIO/OLO) IN PATIENTS WITH COPD: UNITED KINGDOM PAYER PERSPECTIVE
    Kendall, R.
    Martin, A.
    Shah, D.
    Noorduyn, S. G.
    Dasari, P.
    Risebrough, N.
    Ismaila, A.
    VALUE IN HEALTH, 2023, 26 (12) : S191 - S191
  • [29] IMPACT Study: Cost-Effectiveness of Single-Inhaler Triple Therapy for the Treatment of COPD by Patients' Exacerbation History in Quebec
    Schroeder, M.
    Shah, D.
    Martin, A.
    Ndirangu, K.
    Risebrough, N.
    Ismaila, A. S.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2019, 199
  • [30] Population pharmacokinetic (PK) analysis of fluticasone furoate (FF)/umeclidimium (UMEC)/vilanterol (VI) via a single inhaler in patients with COPD (FULFIL)
    Mehta, Rashmi
    Pefani, Eleni
    Beerahee, Misba
    Barnacle, Helen
    Birk, Ruby
    Brealey, Noushin
    Zhu, Chang-Qing
    Lipson, David A.
    EUROPEAN RESPIRATORY JOURNAL, 2017, 50
12345